Oncology @Point of Care Podcasts

Visit MorningCommutePodcast.com/NSCLC3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss New therapies in the pipeline as well as immunotherapy combinations.  At the time this podcast was recorded, cemiplimab was pending approval.

Visit MorningCommutePodcast.com/NSCLC2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts discuss PD-L1 levels, do they matter, as well as choosing the best candidates for Immune checkpoint inhibitor therapy not combined with chemotherapy, and they will also touch on recognizing adverse events.

Visit MorningCommutePodcast.com/NSCLC1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode our experts discuss the current standards of care regarding patient work-up, diagnosis, as well as PD-L1 expression and emerging immunotherapy biomarkers in treatment selection for non-small cell lung cancer.

Visit http://journalclubpodcasts.com/cll to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this Journal Club Podcast our expert faculty look at treatment of CLL patients with Covid-19, specifically BTK-inhibitors and monoclonal anti-CD20 antibodies.

Visit journalclubpodcasts.com/clinicaloncology to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts discuss the findings of a study published in Lancet Oncology that suggests Covid-19 appears to have a different trajectory for patients depending on the type of cancer that they have. Patients with hematologic cancers–leukemia, lymphoma, myeloma–developed more severe Covid-19 compared with those with solid tumors.

Visit morningcommutepodcast.com/endometrial1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts on endometrial cancer discuss immune checkpoint inhibitors, including therapeutic rationale and their safety and efficacy as single agents and in combination therapies.

Visit morningcommutepodcast.com/endometrial2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts on endometrial cancer discuss patient selection, toxicities, toxicity management, and how new therapies are entering into the clinical domain with increasing frequency.